TSTim Stüdemann

Tim Stüdemann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tim Stüdemann has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optogenetic tachypacing facilitates burst-induced arrhythmia in stem cell-derived human atrial engineered heart tissue

    by Karl-Felix Müller, Bangfen Pan, Julius Ridder, Jessica Schrapers, Julius Hansen, Tandy M Meier, Carl Schulz, Tim Stüdemann, Marta Lemme, Julia Krause, et al.

    Aims: Large animal models for atrial fibrillation (AF) research are ethically challenging and costly. Suitable humanized in vitro models could circumvent these problems. Here, we aimed to combine tissue engineering, human induced pluripotent stem cell-derived atrial cardiomyocytes (hiPSC-aCM), and optogenetic pacing to trigger an in vitro fibrillation-like state, which can be analysed by simple video recording. Methods and results: Atrial engineered heart tissue (aEHT) was created from hiPSC-aCM and transduced with adeno-associated virus vectors to express the channelrhodopsins CheRiff2.0, Chronos, or PsCatCh2.0f, respectively. We developed novel optogenetic hardware, based on microcontroller programmable light-emitting diodes. The interplay between aEHTs and hardware was optimized, and different pacing patterns were evaluated. Electrical burst pacing was evaluated for arrhythmia induction. Tissue constructs were analysed with regard to action potential, gene and protein expression, and structure. We found our optimized CheRiff2.0 best suitable for optogenetic pacing of aEHT at up to 5 Hz. Atrial EHT could be faithfully tachypaced at 4 Hz for 2.5 weeks. After 5 weeks, electrical burst pacing (20 Hz, 0.5 s) successfully induced self-sustained episodes of a state of fast beating, lower force, and incomplete relaxation. The propensity of these burst-evoked episodes of fibrillation was 3.2-fold higher in long-term paced aEHT than in non-paced controls. Action potential shape and gene expression recapitulated typical features of AF in the tachypaced aEHTs. Conclusion: We successfully created a first-of-its-kind in vitro model of AF, recapitulating the self-sustainability of atrial arrhythmia (‘AF begets AF’). Fibrillation-like episodes can be verified by visual inspection, rendering analysis possible without an electrophysiological setup.


  • Open Access

    Contractility governs cardiomyocyte cell cycle activity

    by Nancy Shehata, Rajiven Srikantharajah, Eleonore Baier, Christoph Manthey, Tim Stüdemann, Marie Nehring, Anita Covic, Christian Müller, Bente Siebels, Paula Nissen, et al.

    The heart’s rhythmic contractions keep blood flowing to deliver the oxygen and nutrients that sustain life, but this very strength may also explain why the heart has so little capacity to regenerate. Whereas embryonic and neonatal hearts can repair themselves, this ability is rapidly lost after birth as heart muscle cells (cardiomyocytes) exit the cell cycle. We tested whether the force-generating machinery of the heart acts as a barrier to regeneration. Across human cardiomyocytes, engineered heart tissue, and myocardial slices, we found that active force generation suppresses proliferation, whereas its inhibition, through chemogenetic or pharmacological modulation, enabled cell cycle re-entry. These findings identify contractility as a central regulator of regenerative potential, highlighting new directions for strategies to restore repair in the diseased heart.

  • Open Access

    Impulse initiation in engrafted pluripotent stem cell-derived cardiomyocytes can stimulate the recipient heart

    by Tim Stüdemann, Barbora Schwarzova, Till Schneidewind, Birgit Geertz, Constantin von Bibra, Marie Nehring, Judith Rössinger, J. Simon Wiegert, Thomas Eschenhagen, Florian Weinberger

    Transplantation of pluripotent stem cell-derived cardiomyocytes is a novel promising cell-based therapeutic approach for patients with heart failure. However, engraftment arrhythmias are a predictable life-threatening complication and represent a major hurdle for clinical translation. Catheter-based electrophysiological analysis suggested that the ventricular arrhythmias were caused by an automaticity of the transplanted cells, but whether impulse generation by transplanted cardiomyocytes can propagate to the host myocardium and override the recipient rhythm has not been directly assessed experimentally. We used optogenetics to specifically activate engrafted cardiomyocytes, which resulted in impulse generation in the engrafted cardiomyocytes and stimulated the recipient heart (4/9 hearts). Thus, our study shows that transplanted cardiomyocytes can electrically couple to the host myocardium and stimulate the recipient heart, providing experimental evidence that cardiomyocyte automaticity can serve as a trigger for ventricular arrhythmias.

  • Open Access

    Modulating cardiac physiology in engineered heart tissue with the bidirectional optogenetic tool BiPOLES

    by Barbora Schwarzová, Tim Stüdemann, Muhammed Sönmez, Judith Rössinger, Bangfen Pan, Thomas Eschenhagen, Justus Stenzig, J. Simon Wiegert, Torsten Christ, Florian Weinberger

    Optogenetic actuators are rapidly advancing tools used to control physiology in excitable cells, such as neurons and cardiomyocytes. In neuroscience, these tools have been used to either excite or inhibit neuronal activity. Cell type–targeted actuators have allowed to study the function of distinct cell populations. Whereas the first described cation channelrhodopsins allowed to excite specific neuronal cell populations, anion channelrhodopsins were used to inhibit neuronal activity. To allow for simultaneous excitation and inhibition, opsin combinations with low spectral overlap were introduced. BiPOLES (Bidirectional Pair of Opsins for Light-induced Excitation and Silencing) is a bidirectional optogenetic tool consisting of the anion channel Guillardia theta anion-conducting channelrhodopsin 2 (GtACR2 with a blue excitation spectrum and the red-shifted cation channel Chrimson. Here, we studied the effects of BiPOLES activation in cardiomyocytes. For this, we knocked in BiPOLES into the adeno-associated virus integration site 1 (AAVS1) locus of human-induced pluripotent stem cells (hiPSC), subjected these to cardiac differentiation, and generated BiPOLES expressing engineered heart tissue (EHT) for physiological characterization. Continuous light application activating either GtACR2 or Chrimson resulted in cardiomyocyte depolarization and thus stopped EHT contractility. In contrast, short light pulses, with red as well as with blue light, triggered action potentials (AP) up to a rate of 240 bpm. In summary, we demonstrate that cation, as well as anion channelrhodopsins, can be used to activate stem cell–derived cardiomyocytes with pulsed photostimulation but also to silence cardiac contractility with prolonged photostimulation.


  • Open Access

    Contractile Force of Transplanted Cardiomyocytes Actively Supports Heart Function After Injury

    by Tim Stüdemann, Judith Rössinger, Christoph Manthey, Birgit Geertz, Rajiven Srikantharajah, Constantin von Bibra, Aya Shibamiya, Maria Köhne, Antonius Wiehler, J. Simon Wiegert, et al.

    Background: Transplantation of pluripotent stem cell–derived cardiomyocytes represents a promising therapeutic strategy for cardiac regeneration, and the first clinical studies in patients with heart failure have commenced. Yet, little is known about the mechanism of action underlying graft-induced benefits. Here, we explored whether transplanted cardiomyocytes actively contribute to heart function. Methods: We injected cardiomyocytes with an optogenetic off-on switch in a guinea pig cardiac injury model. Results: Light-induced inhibition of engrafted cardiomyocyte contractility resulted in a rapid decrease of left ventricular function in ≈50% (7/13) animals that was fully reversible with the offset of photostimulation. Conclusions: Our optogenetic approach demonstrates that transplanted cardiomyocytes can actively participate in heart function, supporting the hypothesis that the delivery of new force-generating myocardium can serve as a regenerative therapeutic strategy.


  • Open Access

    Contractile force of transplanted cardiomyocytes contributes to heart function after injury

    by Tim Stüdemann, Judith Rössinger, Christoph Manthey, Birgit Geertz, Rajiven Srikantharajah, Constantin von Bibra, Aya Shibamiya, Maria Köhne, Antonius Wiehler, J. Simon Wiegert, et al.

    Transplantation of pluripotent stem cell-derived cardiomyocytes represents an innovative therapeutic strategy for heart failure. Studies in small and large animals have demonstrated functional recovery of left ventricular function after cardiomyocyte transplantation 1–4 , and first clinical studies are currently underway 5 . Yet, the mechanism of action underlying graft-induced benefit is unknown 6 . Here we demonstrate that transplanted cardiomyocytes actively contribute to heart function. We transplanted cardiomyocytes with an optogenetic off-on switch in a guinea pig cardiac injury model. Light-induced inhibition of engrafted cardiomyocyte contractility resulted in a rapid decrease of left ventricular function that was fully reversible with the offset of photostimulation. Hence, our optogenetic approach demonstrated that transplanted cardiomyocytes actively participate in heart function, supporting the hypothesis that the delivery of new force-generating myocardium can serve as a regenerative therapeutic strategy.


  • Open Access

    Human engineered heart tissue transplantation in a guinea pig chronic injury model

    by Constantin von Bibra, Aya Shibamiya, Birgit Geertz, Eva Querdel, Maria Köhne, Tim Stuedemann, Jutta Starbatty, Arne Hansen, Bernhard Hiebl, Thomas Eschenhagen, et al.

    A bstract: Myocardial injury leads to an irreversible loss of cardiomyocytes (CM). The implantation of human engineered heart tissue (EHT) has become a promising regenerative approach. Previous studies exhibited beneficial, dose-dependent effects of human induced pluripotent stem cell (hiPSC)–derived EHT patch transplantation in a guinea pig model in the subacute phase of myocardial injury. Yet, advanced heart failure often results from a chronic remodeling process. Therefore, from a clinical standpoint it is worthwhile to explore the ability to repair the chronically injured heart. In this study human EHT patches were generated from hiPSC–derived CMs (15×10 6 cells) and implanted epicardially four weeks after injury in a guinea-pig cryo-injury model. Cardiac function was evaluated by echocardiography after a follow-up period of four weeks. Hearts revealed large transmural myocardial injuries amounting to 27% of the left ventricle. EHT recipient hearts demonstrated compact muscle islands of human origin in the scar region, as indicated by a positive staining for human Ku80 and dystrophin, remuscularizing 5% of the scar area. Echocardiographic analysis demonstrated no significant difference between animals that received EHT patches and animals in the control group (fractional area change 36% vs. 34%). Thus, EHT patches engrafted in the chronically injured heart but in contrast to the subacute model, grafts were smaller and EHT patch transplantation did not improve left ventricular function, highlighting the difficulties for a regenerative approach.

  • Open Access

    Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner

    by Eva Querdel, Marina Reinsch, Liesa Castro, Deniz Köse, Andrea Bähr, Svenja Reich, Birgit Geertz, Bärbel Ulmer, Mirja Schulze, Marc D. Lemoine, et al.

    Background: Human engineered heart tissue (EHT) transplantation represents a potential regenerative strategy for patients with heart failure and has been successful in preclinical models. Clinical application requires upscaling, adaptation to good manufacturing practices, and determination of the effective dose. Methods: Cardiomyocytes were differentiated from 3 different human induced pluripotent stem cell lines including one reprogrammed under good manufacturing practice conditions. Protocols for human induced pluripotent stem cell expansion, cardiomyocyte differentiation, and EHT generation were adapted to substances available in good manufacturing practice quality. EHT geometry was modified to generate patches suitable for transplantation in a small-animal model and perspectively humans. Repair efficacy was evaluated at 3 doses in a cryo-injury guinea pig model. Human-scale patches were epicardially transplanted onto healthy hearts in pigs to assess technical feasibility. Results: We created mesh-structured tissue patches for transplantation in guinea pigs (1.5×2.5 cm, 9–15×10 6 cardiomyocytes) and pigs (5×7 cm, 450×10 6 cardiomyocytes). EHT patches coherently beat in culture and developed high force (mean 4.6 mN). Cardiomyocytes matured, aligned along the force lines, and demonstrated advanced sarcomeric structure and action potential characteristics closely resembling human ventricular tissue. EHT patches containing ≈4.5, 8.5, 12×10 6 , or no cells were transplanted 7 days after cryo-injury (n=18–19 per group). EHT transplantation resulted in a dose-dependent remuscularization (graft size: 0%–12% of the scar). Only high-dose patches improved left ventricular function (+8% absolute, +24% relative increase). The grafts showed time-dependent cardiomyocyte proliferation. Although standard EHT patches did not withstand transplantation in pigs, the human-scale patch enabled successful patch transplantation. Conclusions: EHT patch transplantation resulted in a partial remuscularization of the injured heart and improved left ventricular function in a dose-dependent manner in a guinea pig injury model. Human-scale patches were successfully transplanted in pigs in a proof-of-principle study.